\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\\.\ \(14\)\
\-\ home\\ exercise\\,\\ physical\\ therapy\\,\\ oral\\ bisphosphonates\\,\\ calcitonin\\,\\ nsaids\\,\\ and\\ analgesics\\ are\\ the\\ mainstays\\ of\\ treatment\\.\\ \\ untreated\\ patients\\ should\\ get\\ alkaline\\ phosphatase\\ levels\\ and\\ radiographs\\ annually\\ while\\ treated\\ patients\\ should\\ get\\ alkaline\\ phosphatase\\ levels\\ every\\ 3\\-4\\ months\\ with\\ radiographs\\ annually\\.\ \(0\)\
\-\ ap\\ pelvis\\:\\ \\ coarsened\\ and\\ thickened\\ trabeculae\\ along\\ the\\ right\\ femoral\\ neck\\ and\\ greater\\ trochanter\\.\ \(0\)\
\-\ axial\\ ct\\ images\\ through\\ the\\ right\\ hip\\ and\\ pelvis\\:\\ \\ thickened\\ trabecular\\ markings\\ with\\ thickening\\ of\\ cortical\\ bone\\ along\\ the\\ right\\ femoral\\ neck\\ and\\ greater\\ trochanter\\.\\ \\ areas\\ of\\ increased\\ sclerosis\\ are\\ also\\ present\\ along\\ the\\ right\\ femoral\\ neck\\ and\\ greater\\ trochanter\\.\ \(0\)\
\-\ paget\\ disease\\ of\\ bone\ \(0\)\
\-\ paget\\'s\\ disease\ \(1\)\
\-\ osteosclerotic\\ bone\\ metastases\ \(0\)\
\-\ 62\\ y\\.o\\.\\ woman\\ for\\ metastatic\\ skeletal\\ survey\\ for\\ paget\\ disease\\.\ \(0\)\
\-\ the\\ patient\\ in\\ this\\ case\\ is\\ over\\ 40\\ years\\ of\\ age\\ and\\ paget\\ disease\\ of\\ bone\\ affects\\ approximately\\ 3\\-4\\%\\ of\\ the\\ population\\ over\\ 40\\ years\\ of\\ age\\.\\ \\ the\\ proximal\\ femur\\ was\\ affected\\ in\\ this\\ patient\\.\\ \\ the\\ pelvis\\ is\\ affected\\ in\\ 30\\-75\\%\\ of\\ cases\\ while\\ the\\ proximal\\ long\\ bones\\ are\\ affected\\ in\\ 25\\-30\\%\\ of\\ cases\\.\\ other\\ frequent\\ sites\\ of\\ involvement\\ include\\ the\\ skull\\ \\(25\\-65\\%\\ of\\ cases\\)\\ and\\ spine\\ \\(30\\-75\\%\\)\\.\\ \\ pelvic\\ involvement\\ is\\ more\\ often\\ asymmetric\\ than\\ symmetric\\,\\ and\\ appendicular\\ involvement\\ is\\ frequently\\ unilateral\\ as\\ in\\ this\\ case\\.\ \(0\)\
\-\ the\\ early\\ phase\\ of\\ paget\\ disease\\ is\\ characterized\\ by\\ osteolysis\\ on\\ radiographs\\.\\ \\ when\\ this\\ occurs\\ in\\ the\\ skull\\,\\ it\\ is\\ referred\\ as\\ osteoporosis\\ circumscripta\\.\\ \\ paget\\ disease\\ usually\\ affects\\ the\\ inner\\ table\\ of\\ the\\ skull\\ more\\ than\\ the\\ outer\\ table\\.\\ \\ this\\ is\\ in\\ contradistinction\\ to\\ fibrous\\ dysplasia\\ thataffects\\ the\\ outer\\ table\\ more\\ than\\ the\\ inner\\ table\\.\\ \\ in\\ long\\ bones\\,\\ osteolysis\\ begins\\ as\\ a\\ subchondral\\ lucency\\ likened\\ to\\ a\\ blade\\ of\\ grass\\ or\\ flame\\.\ \(0\)\
\-\ the\\ next\\ phase\\ of\\ paget\\ disease\\ is\\ the\\ mixed\\ phase\\.\\ \\ the\\ characteristic\\ manifestations\\ are\\ coarsening\\ and\\ thickening\\ of\\ the\\ trabecular\\ pattern\\ and\\ cortex\\.\\ \\ paget\\ disease\\ of\\ the\\ pelvis\\ usually\\ manifests\\ with\\ cortical\\ thickening\\ and\\ sclerosis\\ of\\ the\\ iliopectineal\\ and\\ ischiopubic\\ lines\\.\\ \\ the\\ findings\\ are\\ often\\ asymmetric\\ and\\ more\\ commonly\\ seen\\ on\\ the\\ right\\ side\\.\\ \\ within\\ the\\ spine\\,\\ osteoblastic\\ activity\\ is\\ seen\\ on\\ all\\ four\\ margins\\ of\\ the\\ vertebral\\ body\\ with\\ a\\ \\‚\\Ä\\úpicture\\ frame\\ appearance\\‚\\Ä\\ù\\ unlike\\ the\\ rugger\\ jersey\\ vertebrae\\ in\\ renal\\ osteodystrophy\\ which\\ only\\ involves\\ only\\ the\\ superior\\ and\\ inferior\\ endplates\\.\ \(0\)\
\-\ the\\ blastic\\ phase\\ is\\ the\\ next\\ phase\\ of\\ paget\\ disease\\.\\ \\ in\\ the\\ long\\ bones\\ and\\ pelvis\\,\\ areas\\ of\\ sclerosis\\ may\\ develop\\ and\\ can\\ be\\ extensive\\ obliterating\\ areas\\ of\\ previous\\ trabecular\\ thickening\\.\\ \\ bone\\ enlargement\\ is\\ common\\ in\\ this\\ phase\\.\\ \\ the\\ skull\\ can\\ have\\ a\\ \\‚\\Ä\\úcotton\\ wool\\‚\\Ä\\ù\\ appearance\\ while\\ the\\ spine\\ can\\ show\\ an\\ ivory\\ vertebral\\ body\\ on\\ radiography\\.\ \(0\)\
\-\ bone\\ scintigraphy\\ typically\\ demonstrates\\ marked\\ increased\\ uptake\\ of\\ radionuclide\\ in\\ all\\ phases\\ of\\ the\\ disease\\.\\ \\ in\\ the\\ quiescent\\ late\\ phase\\ of\\ the\\ disease\\,\\ radionuclide\\ activity\\ may\\ be\\ normal\\ with\\ persistent\\ abnormalities\\ seen\\ on\\ radiographs\\.\\ \\ patients\\ with\\ normal\\ bone\\ scans\\ and\\ abnormal\\ radiographic\\ findings\\ are\\ almost\\ always\\ asymptomatic\\ with\\ regard\\ to\\ paget\\ disease\\.\ \(0\)\
\-\ ct\\ may\\ show\\ areas\\ of\\ lysis\\ with\\ loss\\ of\\ normal\\ trabeculae\\.\\ \\ cortical\\ and\\ trabecular\\ thickening\\ are\\ well\\ demonstrated\\ as\\ well\\.\\ \\ areas\\ of\\ sclerosis\\ are\\ also\\ seen\\ in\\ the\\ blastic\\ phase\\.\ \(0\)\
\-\ mri\\ often\\ shows\\ maintenance\\ of\\ the\\ yellow\\ marrow\\.\\ \\ bone\\ enlargement\\ as\\ well\\ as\\ trabecular\\ and\\ cortical\\ thickening\\ have\\ low\\ signal\\ on\\ all\\ mr\\ pulse\\ sequences\\.\\ \\ \\ in\\ the\\ lytic\\ or\\ mixed\\ active\\ phase\\,\\ the\\ marrow\\ has\\ decreased\\ signal\\ intensity\\ on\\ t1\\ and\\ heterogeneous\\ high\\ signal\\ intensity\\ on\\ t2\\.\\ \\ the\\ increased\\ blood\\ flow\\ in\\ paget\\ disease\\ is\\ reflected\\ as\\ increased\\ enhancement\\ with\\ gadolinium\\.\ \(0\)\
\-\ complications\\ from\\ paget\\ disease\\ include\\ osseous\\ weakening\\ \\(deformity\\ and\\ fracture\\)\\,\\ arthritis\\,\\ neurologic\\ symptoms\\,\\ and\\ sarcomatous\\ transformation\\ which\\ occurs\\ in\\ 1\\%\\ of\\ cases\\.\\ \\ sarcomatous\\ transformation\\ is\\ seen\\ on\\ images\\ as\\ focal\\ bone\\ destruction\\ extending\\ through\\ the\\ cortex\\ with\\ an\\ associated\\ soft\\ tissue\\ mass\\.\\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ \\ manaster\\ bj\\,\\ disler\\ dg\\,\\ may\\ da\\.\\ muskuloskeletal\\ imaging\\:\\ \\ the\\ requisites\\.\\ 2nd\\ ed\\.\\ philadelphia\\,\\ pa\\:\\ mosby\\,\\ inc\\.\\ 2002\\:\\ 416\\-417\\.\\ \ \(0\)\
\-\ 2\\.\\ \\ resnick\\ d\\.\\ \\ diagnosis\\ of\\ bone\\ and\\ joint\\ disorders\\.\\ \\ 4th\\ ed\\.\\ \\ philadelphia\\,\\ pa\\:\\ w\\.b\\.\\ saunders\\ company\\ 2002\\:\\ 1947\\-1995\\.\ \(0\)\
\-\ 3\\.\\ \\ smith\\ se\\,\\ et\\ al\\.\\ \\ from\\ the\\ archives\\ of\\ the\\ afip\\:\\ \\ radiologic\\ spectrum\\ of\\ paget\\ disease\\ of\\ bone\\ and\\ its\\ complications\\ with\\ pathologic\\ correlation\\.\\ \\ radiographics\\ 2002\\;\\ 22\\:1191\\-1216\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ paget\\:\\ 0\\.08009590733522773\ \(0\)\
\-\ phase\\:\\ 0\\.04704492965582291\ \(0\)\
\-\ trabecular\\:\\ 0\\.03588869673577483\ \(0\)\
\-\ bone\\:\\ 0\\.03037422821334014\ \(0\)\
\-\ disease\\:\\ 0\\.02724455542033233\ \(0\)\
\-\ table\\:\\ 0\\.02629034230571098\ \(0\)\
\-\ trochanter\\:\\ 0\\.02503624116190427\ \(0\)\
\-\ 30\\-75\\:\\ 0\\.022927226070133935\ \(0\)\
\-\ thickening\\:\\ 0\\.022600451779141887\ \(0\)\
\-\ pelvis\\:\\ 0\\.020189150888112017\ \(0\)\
\-\ skull\\:\\ 0\\.018930396314136122\ \(0\)\
\-\ areas\\:\\ 0\\.018695365222666235\ \(0\)\
\-\ 2002\\:\\ 0\\.018227764749967356\ \(0\)\
\-\ annually\\:\\ 0\\.0172127278195846\ \(0\)\
\-\ sarcomatous\\:\\ 0\\.0172127278195846\ \(0\)\
\-\ blastic\\:\\ 0\\.01693870827301028\ \(0\)\
\-\ cortical\\:\\ 0\\.01620325019805364\ \(0\)\
\-\ osteolysis\\:\\ 0\\.01606361793069243\ \(0\)\
\-\ sclerosis\\:\\ 0\\.01596522878245173\ \(0\)\
\-\ radionuclide\\:\\ 0\\.01588418263423742\ \(0\)\
\-\ \\%\\:\\ 0\\.015552569831048175\ \(0\)\
\-\ trabeculae\\:\\ 0\\.015410004333082794\ \(0\)\
\-\ cases\\:\\ 0\\.014807858850356997\ \(0\)\
\-\ phosphatase\\:\\ 0\\.01455563744889024\ \(0\)\
\-\ affected\\:\\ 0\\.014424673387060117\ \(0\)\
\-\ alkaline\\:\\ 0\\.014169629633238033\ \(0\)\
\-\ radiographs\\:\\ 0\\.014076831423678195\ \(0\)\
\-\ bones\\:\\ 0\\.014067746181242175\ \(0\)\
\-\ get\\:\\ 0\\.013607280846580985\ \(0\)\
\-\ as\\:\\ 0\\.01344684011333293\ \(0\)\
\-\ \\:\\:\\ 0\\.01322818380223145\ \(0\)\
\-\ 3\\-4\\:\\ 0\\.013026933508962753\ \(0\)\
\-\ femoral\\:\\ 0\\.012682697074033049\ \(0\)\
\-\ affects\\:\\ 0\\.012650909506853238\ \(0\)\
\-\ transformation\\:\\ 0\\.012601369337878743\ \(0\)\
\-\ greater\\:\\ 0\\.012521650290001955\ \(0\)\
\-\ philadelphia\\:\\ 0\\.012458170957688813\ \(0\)\
\-\ involvement\\:\\ 0\\.0122182262287171\ \(0\)\
\-\ are\\:\\ 0\\.01211832377143929\ \(0\)\
\-\ inner\\:\\ 0\\.01195321383300492\ \(0\)\
\-\ outer\\:\\ 0\\.011804557360079175\ \(0\)\
\-\ long\\:\\ 0\\.011493712005849378\ \(0\)\
\-\ 25\\-65\\:\\ 0\\.011463613035066968\ \(0\)\
\-\ thataffects\\:\\ 0\\.011463613035066968\ \(0\)\
\-\ ischiopubic\\:\\ 0\\.011463613035066968\ \(0\)\
\-\ 416\\-417\\:\\ 0\\.011463613035066968\ \(0\)\
\-\ 1947\\-1995\\:\\ 0\\.011463613035066968\ \(0\)\
\-\ 22\\:1191\\-1216\\:\\ 0\\.011463613035066968\ \(0\)\
\-\ next\\:\\ 0\\.011282656981764087\ \(0\)\
\-\ more\\:\\ 0\\.011116651803964454\ \(0\)\
\-\ along\\:\\ 0\\.01101711525432451\ \(0\)\
\-\ seen\\:\\ 0\\.010979373309932965\ \(0\)\
\-\ spine\\:\\ 0\\.010978297318616442\ \(0\)\
\-\ increased\\:\\ 0\\.010873783000258288\ \(0\)\
\-\ asymmetric\\:\\ 0\\.010798645851376935\ \(0\)\
\-\ often\\:\\ 0\\.010636437770557812\ \(0\)\
\-\ rugger\\:\\ 0\\.010562251291816064\ \(0\)\
\-\ cotton\\:\\ 0\\.010562251291816064\ \(0\)\
\-\ wool\\:\\ 0\\.010562251291816064\ \(0\)\
\-\ while\\:\\ 0\\.010488878699033732\ \(0\)\
\-\ mainstays\\:\\ 0\\.010034988472429634\ \(0\)\
\-\ grass\\:\\ 0\\.010034988472429634\ \(0\)\
\-\ flame\\:\\ 0\\.010034988472429634\ \(0\)\
\-\ iliopectineal\\:\\ 0\\.010034988472429634\ \(0\)\
\-\ jersey\\:\\ 0\\.010034988472429634\ \(0\)\
\-\ quiescent\\:\\ 0\\.010034988472429634\ \(0\)\
\-\ reflected\\:\\ 0\\.010034988472429634\ \(0\)\
\-\ thickened\\:\\ 0\\.009965960474013425\ \(0\)\
\-\ neck\\:\\ 0\\.009788984929851037\ \(0\)\
\-\ marrow\\:\\ 0\\.00977704192098359\ \(0\)\
\-\ mixed\\:\\ 0\\.009760528975135322\ \(0\)\
\-\ may\\:\\ 0\\.009749432347974636\ \(0\)\
\-\ osteosclerotic\\:\\ 0\\.00966088954856516\ \(0\)\
\-\ circumscripta\\:\\ 0\\.00966088954856516\ \(0\)\
\-\ likened\\:\\ 0\\.00966088954856516\ \(0\)\
\-\ coarsening\\:\\ 0\\.00966088954856516\ \(0\)\
\-\ obliterating\\:\\ 0\\.00966088954856516\ \(0\)\
\-\ ivory\\:\\ 0\\.00966088954856516\ \(0\)\
\-\ cortex\\:\\ 0\\.00950965702146156\ \(0\)\
\-\ is\\:\\ 0\\.009505565824449199\ \(0\)\
\-\ all\\:\\ 0\\.009428830257859393\ \(0\)\
\-\ ed\\:\\ 0\\.009392748340415352\ \(0\)\
\-\ blade\\:\\ 0\\.009370715879756044\ \(0\)\
\-\ weakening\\:\\ 0\\.009370715879756044\ \(0\)\
\-\ muskuloskeletal\\:\\ 0\\.009370715879756044\ \(0\)\
\-\ 40\\:\\ 0\\.009350227825456888\ \(0\)\
\-\ in\\:\\ 0\\.009315673488146077\ \(0\)\
\-\ pa\\:\\ 0\\.009294594041370237\ \(0\)\
\-\ levels\\:\\ 0\\.009173605704218369\ \(0\)\
\-\ contradistinction\\:\\ 0\\.00913362672917873\ \(0\)\
\-\ occurs\\:\\ 0\\.009121588365579436\ \(0\)\
\-\ 25\\-30\\:\\ 0\\.00893317070859712\ \(0\)\
\-\ endplates\\:\\ 0\\.00893317070859712\ \(0\)\
\-\ archives\\:\\ 0\\.00893317070859712\ \(0\)\
\-\ afip\\:\\ 0\\.00893317070859712\ \(0\)\
\-\ enlargement\\:\\ 0\\.008818123293849404\ \(0\)\
\-\ complications\\:\\ 0\\.008806691274413673\ \(0\)\
\-\ vertebral\\:\\ 0\\.008795309285857629\ \(0\)\
\-\ signal\\:\\ 0\\.008789626776096666\ \(0\)\
\-\ calcitonin\\:\\ 0\\.008759527805314256\ \(0\)\
\-\ coarsened\\:\\ 0\\.008759527805314256\ \(0\)\
\-\ manaster\\:\\ 0\\.008759527805314256\ \(0\)\
\-\ disler\\:\\ 0\\.008759527805314256\ \(0\)\
\-\ se\\:\\ 0\\.008759527805314256\ \(0\)\
\-\ than\\:\\ 0\\.008734911007483514\ \(0\)\
\-\ patients\\:\\ 0\\.008627729256304392\ \(0\)\
\-\ frame\\:\\ 0\\.0086063639097923\ \(0\)\
\-\ on\\:\\ 0\\.008472066464614894\ \(0\)\
\-\ dg\\:\\ 0\\.00846935413650514\ \(0\)\
\-\ the\\:\\ 0\\.00844956616524111\ \(0\)\
\-\ bisphosphonates\\:\\ 0\\.008345413720634756\ \(0\)\
\-\ activity\\:\\ 0\\.008338222701642493\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.008300392503977008\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.008253865677577073\ \(0\)\
\-\ regard\\:\\ 0\\.008232264985927825\ \(0\)\
\-\ lysis\\:\\ 0\\.008128178239928428\ \(0\)\
\-\ bj\\:\\ 0\\.008128178239928428\ \(0\)\
\-\ intensity\\:\\ 0\\.008032953644679586\ \(0\)\
\-\ manifests\\:\\ 0\\.008031808965346216\ \(0\)\
\-\ maintenance\\:\\ 0\\.008031808965346216\ \(0\)\
\-\ w\\.b\\:\\ 0\\.00794209131711871\ \(0\)\
\-\ company\\:\\ 0\\.00794209131711871\ \(0\)\
\-\ da\\:\\ 0\\.00785816606206335\ \(0\)\
\-\ resnick\\:\\ 0\\.007779330403004268\ \(0\)\
\-\ can\\:\\ 0\\.007561335575301962\ \(0\)\
\-\ well\\:\\ 0\\.007541278100007741\ \(0\)\
\-\ appendicular\\:\\ 0\\.007504546145959785\ \(0\)\
\-\ this\\:\\ 0\\.007499119999850193\ \(0\)\
\-\ \\,\\:\\ 0\\.007392602569392764\ \(0\)\
\-\ analgesics\\:\\ 0\\.007386247344651949\ \(0\)\
\-\ untreated\\:\\ 0\\.007330903242676921\ \(0\)\
\-\ osteodystrophy\\:\\ 0\\.007330903242676921\ \(0\)\
\-\ inc\\:\\ 0\\.007330903242676921\ \(0\)\
\-\ phases\\:\\ 0\\.00727781872444512\ \(0\)\
\-\ body\\:\\ 0\\.0072178510082941075\ \(0\)\
\-\ yellow\\:\\ 0\\.007177739347154967\ \(0\)\
\-\ requisites\\:\\ 0\\.007177739347154967\ \(0\)\
\-\ osteoblastic\\:\\ 0\\.007130447222095311\ \(0\)\
\-\ should\\:\\ 0\\.007085067729229649\ \(0\)\
\-\ unlike\\:\\ 0\\.006998090012329456\ \(0\)\
\-\ saunders\\:\\ 0\\.0069568043188124465\ \(0\)\
\-\ begins\\:\\ 0\\.006916789157997422\ \(0\)\
\-\ survey\\:\\ 0\\.0068402735532861955\ \(0\)\
\-\ show\\:\\ 0\\.006822252105309821\ \(0\)\
\-\ age\\:\\ 0\\.0067643961652647765\ \(0\)\
\-\ usually\\:\\ 0\\.00674883811148702\ \(0\)\
\-\ osteoporosis\\:\\ 0\\.0067333319430950755\ \(0\)\
\-\ only\\:\\ 0\\.006682475054577206\ \(0\)\
\-\ proximal\\:\\ 0\\.0066724139966372305\ \(0\)\
\-\ d\\.\\:\\ 0\\.006603184402708881\ \(0\)\
\-\ mosby\\:\\ 0\\.006542690234132948\ \(0\)\
\-\ years\\:\\ 0\\.006525989953234025\ \(0\)\
\-\ picture\\:\\ 0\\.0065134667544813766\ \(0\)\
\-\ radiographics\\:\\ 0\\.0065134667544813766\ \(0\)\
\-\ scintigraphy\\:\\ 0\\.006456919144676775\ \(0\)\
\-\ spectrum\\:\\ 0\\.0064295414994260175\ \(0\)\
\-\ vertebrae\\:\\ 0\\.0064027283821272716\ \(0\)\
\-\ appearance\\:\\ 0\\.006356063918685674\ \(0\)\
\-\ manifestations\\:\\ 0\\.006325454753426619\ \(0\)\
\-\ radiography\\:\\ 0\\.006325454753426619\ \(0\)\
\-\ through\\:\\ 0\\.006311981842446993\ \(0\)\
\-\ include\\:\\ 0\\.006234469409701656\ \(0\)\
\-\ smith\\:\\ 0\\.006183453073368114\ \(0\)\
\-\ markings\\:\\ 0\\.006161223641171364\ \(0\)\
\-\ lines\\:\\ 0\\.006117873289718059\ \(0\)\
\-\ correlation\\:\\ 0\\.006117873289718059\ \(0\)\
\-\ and\\:\\ 0\\.00608613023281883\ \(0\)\
\-\ 62\\:\\ 0\\.006075921583322453\ \(0\)\
\-\ sites\\:\\ 0\\.006055442575561542\ \(0\)\
\-\ nsaids\\:\\ 0\\.0059958723076404844\ \(0\)\
\-\ every\\:\\ 0\\.0059022786800395875\ \(0\)\
\-\ right\\:\\ 0\\.005862364818663307\ \(0\)\
\-\ subchondral\\:\\ 0\\.00583197019984417\ \(0\)\
\-\ population\\:\\ 0\\.005798191934040191\ \(0\)\
\-\ late\\:\\ 0\\.005781626230818565\ \(0\)\
\-\ radiologic\\:\\ 0\\.005781626230818565\ \(0\)\
\-\ pulse\\:\\ 0\\.005733158877376131\ \(0\)\
\-\ always\\:\\ 0\\.0057173963799348505\ \(0\)\
\-\ exercise\\:\\ 0\\.0057018226594579766\ \(0\)\
\-\ over\\:\\ 0\\.005658368244837354\ \(0\)\
\-\ 4th\\:\\ 0\\.005597735913458581\ \(0\)\
\-\ frequent\\:\\ 0\\.005555557401425871\ \(0\)\
\-\ develop\\:\\ 0\\.005541796531035055\ \(0\)\
\-\ 2nd\\:\\ 0\\.005541796531035055\ \(0\)\
\-\ characterized\\:\\ 0\\.005528179756175113\ \(0\)\
\-\ unilateral\\:\\ 0\\.005514704090329149\ \(0\)\
\-\ skeletal\\:\\ 0\\.00548816459536009\ \(0\)\
\-\ destruction\\:\\ 0\\.00548816459536009\ \(0\)\
\-\ almost\\:\\ 0\\.005375015860653158\ \(0\)\
\-\ disorders\\:\\ 0\\.005316164636221271\ \(0\)\
\-\ of\\:\\ 0\\.005302513690415598\ \(0\)\
\-\ home\\:\\ 0\\.00528209133011721\ \(0\)\
\-\ gadolinium\\:\\ 0\\.005270929114653761\ \(0\)\
\-\ normal\\:\\ 0\\.0052260563898534505\ \(0\)\
\-\ scans\\:\\ 0\\.005174559840071548\ \(0\)\
\-\ involves\\:\\ 0\\.00516428002276711\ \(0\)\
\-\ lucency\\:\\ 0\\.005104251359876131\ \(0\)\
\-\ symmetric\\:\\ 0\\.005075245173251556\ \(0\)\
\-\ margins\\:\\ 0\\.005046871899656445\ \(0\)\
\-\ lytic\\:\\ 0\\.004974103819489937\ \(0\)\
\-\ pathologic\\:\\ 0\\.004863907163501523\ \(0\)\
\-\ case\\:\\ 0\\.004862170176507857\ \(0\)\
\-\ four\\:\\ 0\\.004823892002686499\ \(0\)\
\-\ frequently\\:\\ 0\\.004816034636683947\ \(0\)\
\-\ have\\:\\ 0\\.004812582778582814\ \(0\)\
\-\ femur\\:\\ 0\\.004800460916207073\ \(0\)\
\-\ deformity\\:\\ 0\\.00478507150444244\ \(0\)\
\-\ metastases\\:\\ 0\\.004747376397975272\ \(0\)\
\-\ arthritis\\:\\ 0\\.004747376397975272\ \(0\)\
\-\ findings\\:\\ 0\\.004730395151599375\ \(0\)\
\-\ osseous\\:\\ 0\\.004717987799903437\ \(0\)\
\-\ al\\:\\ 0\\.004710743267979568\ \(0\)\
\-\ characteristic\\:\\ 0\\.004703538872172526\ \(0\)\
\-\ oral\\:\\ 0\\.004682162114899236\ \(0\)\
\-\ sequences\\:\\ 0\\.004640434787784151\ \(0\)\
\-\ neurologic\\:\\ 0\\.004640434787784151\ \(0\)\
\-\ references\\:\\ 0\\.004620062724397416\ \(0\)\
\-\ pelvic\\:\\ 0\\.004560794182789718\ \(0\)\
\-\ et\\:\\ 0\\.004547982353865126\ \(0\)\
\-\ fibrous\\:\\ 0\\.004491841688240667\ \(0\)\
\-\ extensive\\:\\ 0\\.004443895607865729\ \(0\)\
\-\ persistent\\:\\ 0\\.004432180302348998\ \(0\)\
\-\ hip\\:\\ 0\\.004426361992342599\ \(0\)\
\-\ uptake\\:\\ 0\\.004414802892970367\ \(0\)\
\-\ dysplasia\\:\\ 0\\.004386346831527574\ \(0\)\
\-\ also\\:\\ 0\\.004381325341144737\ \(0\)\
\-\ marked\\:\\ 0\\.004336644344115093\ \(0\)\
\-\ previous\\:\\ 0\\.00431514980321625\ \(0\)\
\-\ images\\:\\ 0\\.004263365128606903\ \(0\)\
\-\ pattern\\:\\ 0\\.00424764933559334\ \(0\)\
\-\ active\\:\\ 0\\.004242599270539506\ \(0\)\
\-\ radiographic\\:\\ 0\\.004217639001025662\ \(0\)\
\-\ referred\\:\\ 0\\.004193148821138675\ \(0\)\
\-\ commonly\\:\\ 0\\.004193148821138675\ \(0\)\
\-\ its\\:\\ 0\\.004193148821138675\ \(0\)\
\-\ which\\:\\ 0\\.0041486205129845225\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.004086079527691815\ \(0\)\
\-\ abnormalities\\:\\ 0\\.004081618493755808\ \(0\)\
\-\ ap\\:\\ 0\\.004063925838286655\ \(0\)\
\-\ early\\:\\ 0\\.004063925838286655\ \(0\)\
\-\ typically\\:\\ 0\\.003922530259435595\ \(0\)\
\-\ side\\:\\ 0\\.0038497353729051637\ \(0\)\
\-\ 3\\.\\:\\ 0\\.003802177128921622\ \(0\)\
\-\ inferior\\:\\ 0\\.003770242342469523\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.0037562970064968625\ \(0\)\
\-\ available\\:\\ 0\\.0037356554601297755\ \(0\)\
\-\ extending\\:\\ 0\\.0037356554601297755\ \(0\)\
\-\ flow\\:\\ 0\\.0036723717514415034\ \(0\)\
\-\ joint\\:\\ 0\\.0035935360923824203\ \(0\)\
\-\ superior\\:\\ 0\\.0035484313355711203\ \(0\)\
\-\ 2\\.\\:\\ 0\\.0035337375055920135\ \(0\)\
\-\ mr\\:\\ 0\\.003530818559098094\ \(0\)\
\-\ t1\\:\\ 0\\.003522100827339719\ \(0\)\
\-\ 1\\.\\:\\ 0\\.0034709872123505864\ \(0\)\
\-\ approximately\\:\\ 0\\.003437994572894126\ \(0\)\
\-\ be\\:\\ 0\\.0034271956393860316\ \(0\)\
\-\ renal\\:\\ 0\\.0033387198302445636\ \(0\)\
\-\ treated\\:\\ 0\\.003326203948093445\ \(0\)\
\-\ decreased\\:\\ 0\\.0033039745158966963\ \(0\)\
\-\ from\\:\\ 0\\.0032937209704921\ \(0\)\
\-\ demonstrated\\:\\ 0\\.003260624164443391\ \(0\)\
\-\ loss\\:\\ 0\\.003225571095537633\ \(0\)\
\-\ y\\.o\\:\\ 0\\.0032072554389944085\ \(0\)\
\-\ when\\:\\ 0\\.0031824853545071594\ \(0\)\
\-\ focal\\:\\ 0\\.0031735937635089754\ \(0\)\
\-\ axial\\:\\ 0\\.0031713803329881294\ \(0\)\
\-\ abnormal\\:\\ 0\\.0031691706636084675\ \(0\)\
\-\ t2\\:\\ 0\\.0031451089320550744\ \(0\)\
\-\ ct\\:\\ 0\\.003108722115453948\ \(0\)\
\-\ low\\:\\ 0\\.0030899454523620282\ \(0\)\
\-\ an\\:\\ 0\\.0030732506223269955\ \(0\)\
\-\ shows\\:\\ 0\\.0030551023403496474\ \(0\)\
\-\ high\\:\\ 0\\.003041022186055677\ \(0\)\
\-\ months\\:\\ 0\\.003035034193355094\ \(0\)\
\-\ blood\\:\\ 0\\.0030330443075543556\ \(0\)\
\-\ enhancement\\:\\ 0\\.0029785289546463405\ \(0\)\
\-\ therapy\\:\\ 0\\.002970924312406519\ \(0\)\
\-\ fracture\\:\\ 0\\.002929875592032222\ \(0\)\
\-\ common\\:\\ 0\\.0029080197814777596\ \(0\)\
\-\ \\(\\:\\ 0\\.0028180561491958148\ \(0\)\
\-\ metastatic\\:\\ 0\\.0027972814091236546\ \(0\)\
\-\ \\)\\:\\ 0\\.0027836320888685504\ \(0\)\
\-\ symptoms\\:\\ 0\\.0027693855356282692\ \(0\)\
\-\ physical\\:\\ 0\\.0027262747328754724\ \(0\)\
\-\ soft\\:\\ 0\\.0027060165981710664\ \(0\)\
\-\ 1\\:\\ 0\\.0026441175136016994\ \(0\)\
\-\ tissue\\:\\ 0\\.002633837696297261\ \(0\)\
\-\ \\;\\:\\ 0\\.002633837696297261\ \(0\)\
\-\ associated\\:\\ 0\\.0026221879868760754\ \(0\)\
\-\ or\\:\\ 0\\.0026047405694764824\ \(0\)\
\-\ imaging\\:\\ 0\\.0026034770148967525\ \(0\)\
\-\ woman\\:\\ 0\\.0025668438849010483\ \(0\)\
\-\ other\\:\\ 0\\.0025612985028640426\ \(0\)\
\-\ mri\\:\\ 0\\.0025530245187446294\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0025516506252021066\ \(0\)\
\-\ present\\:\\ 0\\.002509764309404006\ \(0\)\
\-\ it\\:\\ 0\\.0024978522555695925\ \(0\)\
\-\ \\'s\\:\\ 0\\.002449995602557926\ \(0\)\
\-\ demonstrates\\:\\ 0\\.002427335762878005\ \(0\)\
\-\ \\.\\:\\ 0\\.002354325540916333\ \(0\)\
\-\ treatment\\:\\ 0\\.0022491768005213097\ \(0\)\
\-\ patient\\:\\ 0\\.0022278073625913862\ \(0\)\
\-\ within\\:\\ 0\\.002119806772933786\ \(0\)\
\-\ has\\:\\ 0\\.0020867359824372927\ \(0\)\
\-\ a\\:\\ 0\\.0020629378508119703\ \(0\)\
\-\ for\\:\\ 0\\.0018962500614895061\ \(0\)\
\-\ by\\:\\ 0\\.001850287260396456\ \(0\)\
\-\ with\\:\\ 0\\.0016736618166304123\ \(0\)\
\-\ to\\:\\ 0\\.0016660654425604145\ \(0\)\
\-\ not\\:\\ 0\\.0016057459970636352\ \(0\)\
\-\ mass\\:\\ 0\\.0015454629479162087\ \(0\)\
\-\ was\\:\\ 0\\.0012851463227746252\ \(0\)\
